aTyr Pharma, Inc.(US:ATYR) Globenewswire·2025-11-14 21:00Core Viewpoint - aTyr Pharma, Inc. is facing a class action securities lawsuit due to alleged securities fraud related to the efficacy of its drug Efzofitimod, which failed to meet its primary endpoint in a clinical study, leading to a significant drop in stock price [1][2]. Group 1: Lawsuit Details - The class action lawsuit aims to recover losses for aTyr investors affected by alleged securities fraud between November 7, 2024, and September 12, 2025 [1]. - The complaint alleges that defendants made positive statements about Efzofitimod while concealing material adverse facts regarding its efficacy, particularly its ability to allow patients to taper steroid usage [2]. - The truth about the drug's efficacy was revealed on September 15, 2025, when aTyr announced that the EFZO-FIT study did not meet its primary endpoint, resulting in a stock price decline from $6.03 to $1.02, an 83.2% drop in one day [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the relevant time frame have until December 8, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving as lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the United States [4].